← Leaderboards
Michael John Hayman
State University New York Stony Brook
$2,805,758
Attributed
$2,805,758
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $286.1K · FY2005–15$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$2,805,758 · 6
By mechanism
R01$1,707,235 · 1
R21$946,039 · 3
P01$152,484 · 2
Top collaborators
No co-investigators on record.
Most similar at State University New York Stony Brook
Same institution · by research overlap
- Ute M Moll$14,001,329
- Gary S Goldberg$2,538,407
- Gregory J Zelinsky$3,664,654
- Ghassan J Samara$124,520
- Edward L Chan$169,711
Others in their field
Top investigators on “Oncoproteins”
- Donald W. Kufe · Dana-Farber Cancer Inst$17,291,465
- Peter M Howley · Dana-Farber Cancer Inst$16,679,069
- Michael L Cleary · Stanford University$14,032,178
- Karl Munger · Harvard University (Medical School)$13,542,361
- Kevin Michael Haigis · Massachusetts Institute Of Technology$13,116,429
- Kevin Bruce Jones · University Of Utah$13,024,830
Research focus
OncoproteinsOncogenesCell DifferentiationLaboratory MouseLeukemiaChickensCell Growth RegulationNeoplasm /Cancer GeneticsTransforming Growth FactorsMalignant NeoplasmsTumorProteinsRetinoblastoma ProteinTranscription FactorCarcinogenesisProtein Structure FunctionHematopoiesisGrowth Factor ReceptorsClinical TrialsBiological Signal TransductionProtein Protein InteractionGenetically Modified AnimalsProtein Tyrosine KinaseEpidermal Growth Factor Receptor
Grant awards (14)
Validating the prognostic value of EGFR768 in neuroblastoma$204,076
R21 · FY2015 · CA · contact PI
HDAC3 - a therapeutic target in PDA$199,846
R21 · FY2014 · CA · contact PI
HDAC3 - a therapeutic target in PDA$163,277
R21 · FY2013 · CA · contact PI
Ron/EGFR interactions and therapeutic resistance in head and neck cancers$207,240
R21 · FY2010 · CA · contact PI
Ron/EGFR interactions and therapeutic resistance in head and neck cancers$171,600
R21 · FY2009 · CA · contact PI
MECHANISM OF ACTION OF THE SKI ONCOGENE$286,138
R01 · FY2005 · CA
MECHANISM OF ACTION OF THE SKI ONCOGENE$286,138
R01 · FY2004 · CA
MECHANISM OF ACTION OF THE SKI ONCOGENE$286,138
R01 · FY2003 · CA
MECHANISM OF ACTION OF THE SKI ONCOGENE$286,138
R01 · FY2002 · CA
GROWTH FACTOR RECEPTORS IN HEMATOPOIETIC MALIGNANCIES$0
P01 · FY2002 · CA
MECHANISM OF ACTION OF THE SKI ONCOGENE$286,138
R01 · FY2001 · CA
GROWTH FACTOR RECEPTORS IN HEMATOPOIETIC MALIGNANCIES$0
P01 · FY2001 · CA
INTERACTION OF ONCOGENES WITH AVIAN CELLS$276,545
R01 · FY2000 · CA
REGULATION OF HEMATOPOIESIS BY EPIDERMAL GROWTH FACTOR RECEPTOR$152,484
P01 · FY2000 · CA